Gsa Capital Partners LLP Vir Biotechnology, Inc. Transaction History

Gsa Capital Partners LLP

  • $1.32 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 15, 2023
BUY
$9.14 - $24.62 $1.07 Million - $2.88 Million
117,131 New
117,131 $1.1 Million
Q1 2022

May 11, 2022
SELL
$21.19 - $40.01 $295,070 - $557,139
-13,925 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$30.97 - $54.03 $452,409 - $789,270
-14,608 Reduced 51.2%
13,925 $583,000
Q3 2021

Nov 12, 2021
BUY
$34.9 - $54.54 $803,816 - $1.26 Million
23,032 Added 418.69%
28,533 $1.24 Million
Q2 2021

Aug 05, 2021
BUY
$38.75 - $51.0 $213,163 - $280,551
5,501 New
5,501 $260,000

Others Institutions Holding VIR

# of Institutions
219
Shares Held
87.4M
Call Options Held
127K
Put Options Held
1.19M
View Full List

About Vir Biotechnology, Inc.

VIR Quotes by TradingView
  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $944M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Gsa Capital Partners LLP Portfolio

Follow Gsa Capital Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email